Appendiceal Cancer Treatment Global Market Report 2024

The appendiceal cancer treatment market size has grown strongly in recent years. It will grow from $3.76 billion in 2023 to $3.98 billion in 2024 at a compound annual growth rate (CAGR) of 6.0%. The expansion observed in the historical period can be credited to advancements in clinical research and trials, enhancements in diagnostics, collaborative and multidisciplinary approaches, government initiatives and funding, as well as increased awareness and educational efforts.

The appendiceal cancer treatment market size is expected to see strong growth in the next few years. It will grow to $4.88 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period is linked to progress in immunotherapy, targeted therapies, genomic medicine, regulatory approvals, and the adoption of patient-centric care. Noteworthy trends in the forecast period encompass advancements in immunotherapy, precision medicine, and biomarker identification, the utilization of combination therapies, the integration of digital health technologies, and the emphasis on real-world evidence and data-driven decision-making.

The anticipated rise in clinical trials is expected to drive the growth of the appendiceal cancer treatment market in the future. Clinical trials, which are upcoming research studies involving human participants, play a crucial role in investigating and comparing biomedical or behavioral interventions for appendiceal cancer. These trials contribute significantly to advancing our understanding of the disease and enhancing treatment options through more targeted and effective approaches. As of May 2023, a report from Xtalks indicates that there are currently 452,604 registered clinical trials worldwide on ClinicalTrials.gov, with 64,838 actively recruiting participants. This represents a notable increase from the reported over 365,000 registered trials in early 2021, thereby propelling the growth of the appendiceal cancer market.

The expected expansion of the appendiceal cancer treatment market is further driven by the increasing healthcare expenditure. Healthcare expenditure, encompassing spending on healthcare-related goods and services within a healthcare system or economy, is a key factor influencing the growth of this market. For instance, data from the Canadian Institute for Health Information in November 2022 reveals that healthcare expenditure for appendiceal cancer treatment rose to 0.8%, amounting to $331 billion in 2022, compared to 7.6% in 2021. This rise in healthcare expenditure covers the costs associated with diagnosing, managing, and treating patients with appendiceal cancer, providing medical services, therapies, and support systems. Consequently, the upward trend in healthcare expenditure is contributing to the expansion of the appendiceal cancer treatment market.

The growth of the appendiceal cancer treatment market is hindered by the lack of effective treatment options during the forecast period. Ineffectiveness in current treatment options limits therapeutic choices for patients, impeding market growth. According to the American Society of Clinical Oncology in December 2021, surgery is the most common initial step in treating localized cancer of the appendix, while chemotherapy is the predominant treatment for advanced or metastatic appendiceal cancer. Nevertheless, the efficacy of these treatments varies depending on the cancer's stage and type, highlighting the need for more effective alternatives. Therefore, the limitations in current treatment options negatively impact the growth of the appendiceal cancer treatment market.

Major companies in the appendiceal cancer treatment market are focusing on developing innovative products such as tyrosine kinase inhibitors to offer reliable services to customers. Tyrosine kinase inhibitors (TKIs) are medications that block the activity of enzymes involved in cell growth and division. For instance, in June 2021, Hutchmed Limited, a China-based pharmaceutical company, received approval from the National Medical Products Administration for Surufatinib, a novel tyrosine kinase inhibitor for the treatment of advanced solid tumors and neuroendocrine tumors. This inhibitor targets tumor angiogenesis and fibroblast growth factor receptor 1, contributing to both inhibiting angiogenesis and promoting the body's immune response against appendix tumor cells.

In June 2022, Truveta Inc., a US-based medical technology company, partnered with Pfizer Inc., a US-based pharmaceutical company, to enhance the discovery, monitoring, and assessment of possible signals using entire Electronic Medical Record data for over 50 million patients. This collaboration aims to advance medication development for the treatment of appendiceal cancer, with Pfizer Inc. utilizing its expertise in pharmaceuticals to contribute to the ongoing progress in this field.

Major companies operating in the appendiceal cancer treatment market report are Pfizer Inc., Roche Holding AG, F. Hoffman-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, Fresenius Kabi USA, Eli Lilly & Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Johnsons & Johnsons, Becton Dickinson and Company, GE HealthCare Technologies Inc., Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Genetech Inc., Lupin Limited, Gland Pharma Limited, Accord Healthcare Limited, ImmunoGen Inc.

North America was the largest region in the appendiceal cancer treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the appendiceal cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the appendiceal cancer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The appendiceal cancer treatment market consists of revenues earned by entities by providing services such as diagnosis and staging services, appendectomy, hemicolectomy, medical oncology services, radiation oncology services, clinical trial services, multidisciplinary care coordination, palliative and supportive care services, and nutrition services. The market value includes the value of related goods sold by the service provider or included within the service offering. The appendiceal cancer treatment market also includes sales of avastin (bevacizumab), fluorouracil, leucovorin (folinic acid), capecitabine (Xeloda), irinotecan (Camptosar), and oxaliplatin (Eloxatin). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary modalities for treating appendiceal cancer encompass colonic-type adenocarcinoma, mucinous adenocarcinoma of the appendix, goblet cell adenocarcinoma, neuroendocrine carcinoma, and other variants. Colonic-type adenocarcinoma specifically denotes a type of cancer that emerges within the epithelial cells, constituting the linings of both internal and external body surfaces. Treatment options include surgical procedures, chemotherapy, radiation therapy, and other modalities, which can be administered orally, intravenously, or through other means. The end-users of these treatments are hospitals, cancer research institutes, and other relevant institutions.

The appendiceal cancer treatment market research report is one of a series of new reports that provides appendiceal cancer treatment market statistics, including appendiceal cancer treatment industry global market size, regional shares, competitors with an appendiceal cancer treatment market share, detailed appendiceal cancer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the appendiceal cancer treatment industry. This appendiceal cancer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.